- Details
- Akash Patnaik, an Assistant Professor of Medicine at the University of Chicago joins Alicia Morgans to speak about his work and expertise with immunotherapy in prostate cancer. Dr. Patnaik and Dr. Morgans discuss the work that he is doing in the lab to better understand why some patients have exceptional responses to combining two different immunotherapies targeting CTLA-4 and PD-1 in prostate can...
|
- Details
- Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...
|
- Details
- Charles Drake, a leader in the research of immunology in castration-resistant prostate cancer, (mCRPC) discusses the evolution of immunotherapy in prostate cancer. Together with Charles Ryan, in this discussion, he focuses on the best combination therapies and MSI-high disease in metastatic prostate cancer. Biographies: Charles G. Drake, MD, Ph.D., Department of Medicine, Division of Hematology/On...
|
- Details
- Arpit Rao joins Alicia Morgans to discuss new data on PARP inhibitors in prostate cancer. Dr. Rao shares his thoughts about the future of PARP, where things stand with PARP inhibitors currently, highlighting the PROfound study, TRITON2, and last year's TOPARP-B in advanced castration-resistant prostate cancer and what he thinks in terms of personalized medicine for this population. Biographies: Ar...
|
- Details
- Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) and key takeaways from the session when thinking about managing these patients with this disease. She highlights Professor Michael Hofman's presentation on PSMA Targeted Therapies focusing on Lutetium PSMA sc...
|
- Details
- Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting. She highl...
|
- Details
- In this presentation, Robert Bristow speaks on the concept of local radiotherapy to the primary tumor in the metastatic prostate cancer setting at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Bristow's presentation covers the concept of oligometastatic disease, the rationale for treating the primary tumor, and the future role of metastases-directed therapy including differen...
|
- Details
- Robert Reiter presented the definitions and concepts of oligometastatic prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). With improved imaging, this definition has become important from a terminology and treatment standpoint. Dr. Reiter highlights several potential pathways of oligometastasis from the primary tumor and highlights two important clinical questions r...
|
- Details
- Kim Chi presented an update on the utilization of PARP inhibitors during the Management of Castration-Resistant Prostate Cancer (CRPC) session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Leading his presentation with the most recent positive phase III results from Lynparza® (olaparib), the only PARP inhibitor with positive phase III results in four different cancer types. He...
|
- Details
- Eric Small presents on the treatment of oligometastatic and oligoprogressive castration-resistant prostate cancer (CRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Small argues that instead of oligoprogressive CRPC, two other definitions should be used: (i) synchronous oligometastatic CRPC – metastases are synchronous with the emergence of ADT resistance, and (ii) metac...
|
